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PASIAbstract Introduction: Tumor necrosis factor-alpha (TNF-a) is an important proinﬂammatory
cytokine playing a key role in the pathogenesis of psoriasis (Ps) and psoriatic arthritis (PsA). TNFa
gene promoter region single nucleotide polymorphisms (SNPs) affect the clinical course, severity
and the response to the treatment.
Aim of the work: To ﬁnd out whether TNF-a-238G/A and -308G/A promoter polymorphism in
Ps patients increases arthritis risk.
Patients and methods: The study included 129 psoriatic patients (71 with psoriasis only and 58
with PsA). Two single nucleotide polymorphisms in the TNFa gene promoter region (238G/A
and -308G/A) were genotyped by real-time polymerase chain reaction.
Results: Ps patients without arthritis had a mean age of 44.20 ± 13.85 years (range 18–68 years),
while PsA patients had a mean age of 49.15 ± 13.47 years (range 18–82 years) and presented by
dactylitis (67.2%), enthesitis (62.1%) followed by spondylitis (60.3%). Periosteal reaction was pre-
sent in 19%. The psoriatic arthritis severity index (PASI) was comparable between those with (8.2
± 7.1) and without (7.3 ± 5.12.1) arthritis. The allele positivity of TNF-238A and -308A was not
associated with the risk of arthritis among psoriatic patients (OR: 1.002; 95%CI: 0.38–2.6, p= 0.99
and OR: 1.27; 95%CI: 0.51–3.2, p= 0.6, respectively). In addition, none of the genotypes of the
studied TNF-a polymorphisms were signiﬁcantly associated with arthritis. Only spondylitis was sig-
niﬁcantly associated more frequently with the GG (67.3%) than the GA (22.2%) TNF-a-308G/A
genotype (p= 0.02).
Conclusion: None of the haplotypes nor alleles of TNF-a-238G/A and -308G/A polymorphisms
were signiﬁcantly associated with arthritis development among psoriatic patients.
 2016 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).iz Mart
314 S. Isık et al.1. Introduction
Psoriatic arthritis (PsA) is a chronic, seronegative spondy-
loarthritis associated with psoriasis (Ps). The pathogenesis,
clinical manifestations and treatments differ from those of
rheumatoid arthritis (RA). The risk of developing PsA is
7–42% among psoriatic patients [1]. The disease affect the
synovium and enthesis of peripheral and axial joints [2,3].
PsA manifests as peripheral arthritis, dactylitis, enthesitis,
spondylitis, or sacroiliitis and as a sum the disease causes
permanent joint damage.
Psoriasis vulgaris and PsA are linked diseases but immune-
mediated pathogenesis is still unclear. Leading to disability
and negatively affecting the quality of life, there is a great need
for illuminating the etiology of the diseases. Recent studies
focus on the molecular pathway of PsA to understand the
immunopathogenesis and ﬁnd new treatment options [4].
PsA patients have a high risk for cardiovascular and metabolic
disorders like psoriasis [5].
Tumor necrosis factor-alpha (TNF-a) is an important
macrophage-derived proinﬂammatory cytokine playing a key
role in the etiopathogenesis of a variety of autoimmune and
inﬂammatory disorders such as RA, systemic lupus erythe-
matosus and Behc¸et disease as well as Ps and PsA [6–9].
TNF-a stimulates the production of cytokines including
IL-1, 6 and 8 and then the transcription factor kappa B is
up-regulated and allows keratinocyte proliferation. All these
signals may cause pathological inﬂammation in various
organs, particularly in the skin and joints [8]. TNF-a level in
PsA patients is higher both in psoriasis lesions and in the syn-
ovium [9]. Thus, anti-TNFs are widely used to suppress the
inﬂammatory response in the treatment of Ps and PsA [10–14].
There are various single nucleotide polymorphisms (SNP)
in the TNF-a gene and mostly TNF-a 238G/A and 308G/A
polymorphisms are found to be relevant with psoriasis [15].
It’s also reported that ﬁve microsatellite regions in TNF locus
increase the risk of Ps and PsA [16–17]. Aside TNF-a polymor-
phisms are linked with psoriasis related parameters such as
onset, severity and progressive joint involvement [9,18–20].
In this study we aimed to determine whether TNF-238G/A
and 308G/A polymorphisms are related with PsA in psoriatic
patients.
2. Patients and methods
The study sample was composed of 129 psoriatic patients, of
whom 58 were with arthritis, while 71 were without. Cases
were selected from the Dermatology and Venereology Depart-
ments and outpatient clinics of C¸anakkale Onsekiz Mart
University Training and Research Hospital. All participants
were collected in the period from January 2013 to November
2015. All patients were subjected to anamnesis (age, sex, pso-
riasis duration, age of onset) and thorough skin biopsy and
physical examination by the same dermatologist. Patients with
PsA fulﬁlled the ClASsiﬁcation criteria for Psoriatic Arthritis
(CASPAR) [21]. The study was approved by the local ethics
committee of C¸anakkale Onsekiz Mart University Training
and Research Hospital. Patients were recruited and examined
after detailed information about the study design and all of
them signed written consent forms.Patients were subjected to physical examination and labo-
ratory monitoring by specialist during their follow-up visits.
Psoriasis Area and Severity Index (PASI) [22] was used as a
measure for psoriasis severity. Radiographs of the hands, feet,
spine (anteroposterior and lateral) and pelvis (anteroposterior)
and magnetic resonance imaging of sacroiliac joints were per-
formed when necessary.
2.1. DNA isolation and TNF-a genotyping
Whole venous blood samples of controls and patients were
collected using vacuum collection tubes containing EDTA.
The DNA isolation from peripheral blood leukocytes were
performed by spin column methods with High Pure
polymerase chain reaction (PCR) Template preparation Kit
(Roche, Germany) according to the manufacturer’s instruc-
tions. All samples obtained from individuals were ampliﬁed
to determine TNFa-308GA and -238GA polymorphisms by
Real Time PCR method with speciﬁc primers (TIB Molbiol,
LightSNIP) for TNF-a-238GA(rs361525) and -308GA
(rs1800629). The total reaction volume was prepared in 20 ll
for each SNP (single nucleotide polymorphism). Reaction mix-
ture consisted of 2 ll FastStart DNA Master, 1.6 ll MgCl2 for
ﬁnal MgCl2 concentration was 3.0 mM, 1 ll primer and 10.4 ll
H2O) FastStart DNA Master Hybprobe (Roche Diagnostics)
(Taq polymerase, deoxynucleotide triphosphates) and 1–5 ll
(50 ng) DNA were combined for the detection of the each
polymorphism. Same protocol used for both polymorphisms.
Real-time PCR protocol was carried out using a Light Cycler
2.0 (Roche) device; denaturation was at 95 C for 10 min;
quantitation was with 45 cycles at 95 C for 10 s, 60 C for
10 s and 72 C for 15 s; melting was at 95 C for 20 s, 40 C
for 20 s and 85 C in 0.2 continuous mode, with cooling at
40 C. G and A alleles for TNF-a, with melting curve analysis
at channel 530.
2.2. Statistical analysis
Statistical analysis was performed by SPSS 19. Clinical charac-
teristics (continuous data) were analyzed descriptively and
were shown as means and standard deviations (SD). Categor-
ical data was presented as percentages. The odds ratio (OR)
and 95% conﬁdence interval (CI) were considered. The fre-
quencies of alleles and genotypes of TNFa at positions 308
and 238 were evaluated by allele counting methods. The geno-
type frequencies were calculated as follows, the number of
individuals with one particular genotype divided by the total
number of individuals in the population. The allele frequencies
were also determined by counting the number of interested
alleles and divided by the total number of alleles. Genotype
frequency distributions were tested for agreement with the
Hardy–Weinberg Equilibrium examined by chi-square test.
3. Results
Ps patients without arthritis (n= 71) were 34 males and 37
females with a mean age of 44.20 ± 13.85 years (range
18–68 years), while PsA patients (n= 58) were 26 males and
32 females with a mean age of 49.15 ± 13.47 years (range
18–82 years). The clinical characteristics of the psoriatic
308G/A and 238G/A polymorphisms in the TNF-a gene 315patients with and without arthritis are shown in Table 1.
Dactylitis ‘sausage ﬁngers’ is the most frequent ﬁnding among
PsA patients (39/58; 67.2%) and enthesitis was present in 36
patients (62.1%) followed by spondylitis in 35 patients
(60.3%). Periosteal reaction was present in 11 patients (19%).
The genotype frequency of each of the TNF promoter poly-
morphism G238A and G308A was consistent with Hardy–
Weinberg equilibrium in Ps and PsA patients. The genotype
and allele distribution of -238G/A and -308G/A polymor-
phisms are shown in Table 3. For the -238G/A and -308G/A
polymorphisms, the frequency of homozygote GG was the
highest and the frequency of the mutant allele AA was not
found in this study. Regarding the results allele positivity of
TNF-238A and -308A in the promoter region was not associ-
ated with the risk of arthritis among psoriatic patients (OR:
1.002; 95%CI: 0.38–2.6, p= 0.99 and OR: 1.27; 95%CI:
0.51–3.2, p= 0.6, respectively). The risk of arthritis due toTable 1 Clinical features of psoriasis and psoriatic arthritis patient
Feature
Mean ± SD or n (%)
Psoriasis only
(n= 71)
Age (years) 41.2 ± 13.9
Gender F:M 41:30 (57.7/42.3)
Age of onset (years) 28.5 ± 15.5
Type 1 (640 years) 53 (74.65)
Type 2 (>40 years) 18 (25.35)
Psoriasis type
Localised 41 (54.8)
Generalised 22 (30.99)
Palmoplantar 3 (4.2)
Guttate 4 (5.6)
Inverse 1 (1.4)
PASI 7.3 ± 5.12.1
Dactylitis –
Enthesitis –
Spondylitis –
Periosteal reaction –
PsA: psoriatic arthritis, F:M: female; male, PASI: psoriatic arthritis seve
Table 2 Distributions of genotype and carriage rate of TNF-a
association analyses of polymorphisms with arthritis among psoriasi
Tests for deviation from HWE Tests for association OR (9
Ps (n= 71) PsA (n= 58) Allele freq. Diﬀerence
Risk allele A
SNP (TNF 238G/A) G–A
GG (n= 60) (60.4) (n= 49) (49.4) 1.002
(0.4–2.5)
p= 0.99
GA (n= 11) (10.2) (n= 9) (8.3)
AA (n= 0) (0.43) (n= 0) (0.35)
F (p) 0.08 (0.48) 0.08 (0.52)
SNP (TNF 308G/A) G–A
GG= 60 (58.6) (n= 47) (47.5) 1.04
(0.5–2.4)
p= 0.93
GA= 9 (11.8) (n= 11) (9.96)
AA= 2 (0.6) (n= 0) (0.52)
F (p) 0.24 (0.04) 0.11 (0.42)
HWE: Hardy–Weinberg equilibrium, Ps: psoriasis, PSA: psoriatic arthr
polymorphism, TNF: tumor necrosis factor. Bold value is signiﬁcant at psubstitution of G to A in the -238A or -308A promoter regions
were not statistically signiﬁcant on comparing between patients
with Ps only and PsA. There were no signiﬁcant allele frequency
differences between -238G/A (OR: 1.002; 95%CI: 0.4–2.51,
p= 0.99) and -308G/A (OR: 1.04; 95%CI: 0.45–2.42,
p= 0.93) polymorphisms and none of the studied genotypes
were signiﬁcantly associated with PsA (Table 2). The common
OR was 1.002 (x2:0.00, p= 0.99) and 1.2 (x2:0.01, p: 0.93) for
G238A and G308A respectively. Clinical characteristics in PsA
showed no signiﬁcant association with TNF-238A and -308A
polymorphisms as shown in Tables 3 and 4.4. Discussion
Recent studies focus on the genetic background to ﬁgure out
common pathways of psoriasis and psoriatic arthritis.s.
PsA
(n= 58)
All patients
(n= 129)
49.2 ± 13.5 44.8 ± 14.2
35:23 (60.3/39.7) 76:53 (58.9/41.1)
33.8 ± 18.5 30.98 ± 17.1
38 (65.5) 91 (70.5)
20 (34.5) 38 (29.5)
35 (60.4) 76 (58.9)
17 (29.3) 39 (30.2)
4 (6.9) 7 (5.4)
2 (3.4) 6 (4.7)
– 1 (0.8)
8.2 ± 7.1 7.7 ± 6.1
39 (67.2) –
36 (62.1) –
35 (60.3) –
11 (19) –
rity index.
promoter region polymorphisms (-238G/A and -308G/A) and
s patients (n= 129).
5%CI)
Hetero-zygous Homo-zygous Allele positivity
GG  AG GG+ AA AA  GA+AA
1.002
(0.4–2.6)
p= 0.99
1.002
(0.02–62.7)
p= 1
1.002
(0.38–2.6)
p= 0.99
GG  AG GG+ AA AA  GA+AA
1.56
(0.6–4.1)
p= 0.36
0.26
(0–5.4)
p= 0.21
1.28
(0.5–3.2)
p= 0.6
itis, OR: odds ratio, CI: conﬁdence interval, SNP: single nucleotide
< 0.05.
Table 3 Musculoskeletal ﬁndings in psoriatic arthritis patients according to the TNF-a-238G/A promoter polymorphisms.
Musculoskeletal ﬁndings n (%) TNF-238G/A polymorphism in PsA patients (n= 58)
GG (n= 47) GA (n= 11) AA (n= 0) p OR (95%CI)
Spondylitis 30 (63.8) 5 (45.5) NA 0.29 0.47 (0.13–1.78)
Enthesitis 28 (59.6) 8 (72.7) NA 0.42 1.81 (0.42–7.71)
Dactylitis 31 (66) 8 (72.7) NA 0.67 1.38 (0.32–5.91)
Periosteal reaction 10 (21.3) 1 (9.1) NA 0.37 0.37 (0.04–3.24)
TNF: tumor necrosis factor, PsA: psoriatic arthritis, OR: odds ratio, CI: conﬁdence interval, NA: not applicable.
Table 4 Musculoskeletal ﬁndings in psoriatic arthritis patients according to the TNF-a-308G/A promoter polymorphisms.
Musculoskeletal ﬁndings n (%) TNF-308G/A polymorphism in PsA patients (n= 58)
GG (n= 49) GA (n= 9) AA (n= 0) p OR (95%CI)
Spondylitis 33 (67.3) 2 (22.2) NA 0.02 0.14 (0.03–0.74)
Enthesitis 29 (59.2) 7 (77.7) NA 0.3 2.41 (0.45–12.84)
Dactylitis 33 (67.3) 6 (66.6) NA 0.97 0.97 (0.21–4.39)
Periosteal reaction 9 (18.4) 2 (22.2) NA 0.79 1.27 (0.23–7.16)
TNF: tumor necrosis factor, PsA: psoriatic arthritis, OR: odds ratio, CI: conﬁdence interval, NA: not applicable. Bold value is signiﬁcant at
p< 0.05.
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regions such as human leukocyte antigen, major histocompat-
ibility complex, psoriasis susceptibility region 1 and TNF are
widely studied. Currently it has been shown that TNFa poly-
morphism affects the clinical course, severity and predicting
response to the treatment of PsA [20].
The TNF-a is an important pro-inﬂammatory cytokine that
plays an essential role in driving the cytokine cascade at sites of
inﬂammation in PsA patients [23]. TNF-a blockers such as
inﬂiximab, etanercept and adalimumab suppress the immune
system and are widely used in treatments of autoimmune
and immune-mediated disorders such as Ps and PsA. Simone
et al. demonstrated that TNFa 238G/A and 308G/A polymor-
phisms are indicators of the poor response to etanercept ther-
apy [24]. Therewithal, TNFa 238G/A polymorphism is stated
as a protective factor for PsA, but the results are controversial
[24,25].
Association studies between TNFa promotor region poly-
morphisms (238G/A–308G/A) with Ps and PsA differ in
populations. There was no association of the TNFa promo-
tor region polymorphisms with PsA in Jewish and Spanish
populations [26]. Zhu et al. reported increased TNFa-857T/C,
TNFa-238A/G variant susceptibility to Ps and PsA and
TNFa-308A/G variant as protective [9]. Rahman et al.
revealed TNFa-238A/G polymorphism as a risk factor for
PsA, but without any signiﬁcant correlation [25]. Mo¨ssner
et al. have found that TNF-238G/A is associated with psori-
asis vulgaris and -308A allele is decreased in PsA and A
allele has a protective role for PsA [27]. In Brazilian patients,
TNF-308 polymorphisms was reported to be associated with
psoriasis susceptibility and severity [28] while TNF GG
genotype was higher in frequency in Serbian patients with
psoriasis compared to control but without signiﬁcance. How-
ever, lack of TNF G allele was associated with lower psori-
asis severity [29]. Interestingly, PsA skin and joint disease are
similarly responsive to TNF antagonists, while IL-17 antag-
onists have better results in PsA skin than in joints. Genes
selectively expressed in PsA synovium might direct future
therapies for PsA [30].Our ﬁndings demonstrated that the TNFa 238G/A and
308G/A polymorphisms have neither protective nor risk
affects for arthritis among Turkish psoriatic patients. Our
results reﬂect the small sample size of patients but we think
it will help to enrich the data about the relation between TNFa
gene polymorphisms and psoriatic arthritis. A larger scale lon-
gitudinal study including healthy control subjects is recom-
mended to conﬁrm this study results.
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